《大行報告》大摩微升康哲藥業(00867.HK)目標價至17.8元 評級「增持」
摩根士丹利發表報告指出,由於內地醫藥反貪腐行動持續,該行將康哲藥業(00867.HK)的2023至2025年各年收入預測下調6.6%、7.9%及7.7%。另對公司核心產品如Deanxit、Plendil和Ursofalk的收入預測下調,因為基於帶量採購計劃之外的藥品銷售存在明顯阻力。
該行將康哲藥業2023至2025年各年每股盈測分別下調12%、10%和8.3%,認為公司在收入基數較低的情況下,營運費用比率略升。對其目標價由17.6元輕微上調至17.8元,評級「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.